Description
Composition
Active substance:
lipoid PPL-400 – 400.0 mg, based on polyunsaturated phospholipids from soybean lecithin (PPL fraction) – 300.0 mg with an average content of L-alpha-phosphatidylcholine 76% – 228.0 mg
Excipients:
Ethyl alcohol 95% – 4.0 mg. Hard gelatin capsules number 0:
Composition of capsule body: iron oxide black dye – 0.01% colorant red iron oxide – 0.01% iron oxide yellow dye – 0.1714% titanium dioxide – 3% gelatin – up
100 %;
Composition capsule caps: iron oxide black dye – 0.53% colorant red iron oxide – 0.93% iron oxide yellow dye – 0.2% titanium dioxide – 0.3333% gelatin – up
100 %
Description:
hard gelatine capsules № 0.
Housing capsule light brown and beige tint capsule cap dark brown.
The contents of capsules – yellow-brown or brown homogeneous mass of a pasty to solid consistency with a characteristic odor
Product form:
Capsules 300 mg.
10 capsules in blisters of PVC film and aluminum foil printed patent.
Or
90 capsules in cans or in cans PET polymer for medicaments.
One jar or 9 contour of cellular packaging together with instructions for use placed in a cardboard box (pack).
Equipment is allowed to 2 or 3 cartons (packs) in multipacks (transportation) of paperboard for consumer packaging.
Contraindications
Hypersensitivity of phosphatidylcholine or other auxiliary components of the preparation. Intolerance to soy. Children under 12 years of age (lack of sufficient evidence.
Dosage
300 mg
Indications
Chronic hepatitis, liver cirrhosis, fatty liver of different etiology, toxic liver damage, alcoholic hepatitis, liver function abnormalities when other somatic diseases. Toxemia of pregnancy, prevention of gall stones formation relapses, psoriasis (as a means of adjuvant therapy), radiation syndrome.
Interaction with other drugs
No information.
Overdose
No information.
pharmachologic effect
Pharmacological group:
hepatoprotective agent.
Pharmacodynamics:
Essential Phospholipids are the main elements of cell membranes and cell organelles structure liver. In diseases of the liver there is always damage to membranes of liver cells and their organelles,
which leads to impaired activity related enzymes and receptors systems, deterioration of the functional activity of the liver cells and reduce the ability to regenerate.
Phospholipids, make up the drug Esslial forte, correspond in their chemical structure endogenous phospholipids, but superior to the endogenous phospholipids by the activity due to a high content of polyunsaturated (essential) fatty acids. Insertion of these high-energy molecules in damaged areas of the cell membrane of hepatocytes restores the integrity of liver cells and promote their regeneration. Cis double bonds of the polyunsaturated fatty acids prevent the parallel arrangement of the hydrocarbon chains in the phospholipids of cell membranes, the density of the phospholipid cell membranes of hepatocytes structure decreases, resulting in increase of their strength and elasticity, improves metabolism. The resulting functional blocks increases the activity of enzymes immobilized on membranes and promote normal physiological flow path essential metabolic processes.
Phospholipids, make up the drug Esslial forte, regulate the metabolism of lipoproteins transferring neutral fats and cholesterol to places oxidation mainly it happens by increasing the ability to bind with high density lipoprotein cholesterol.
Thus, it appears normalizing action on the metabolism of lipids and proteins; for detoxication function fosfolipidozavisimyh liver and enzyme systems; which ultimately prevents the formation of connective tissue in the liver and contributes to the natural regeneration of liver cells.
When the excretion of bile phospholipids in a reduction in the lithogenic index of bile and stabilization.
Pharmacokinetics:
Over 90% of ingested phospholipids absorbed in the small intestine. Most of them are cleaved by phospholipase A to 1-acyl lysophosphatidylcholine, 50% of which is immediately subjected to inverse acetylation in polyunsaturated phosphatidylcholine still during the suction process in the intestinal mucosa. This polyunsaturated phosphatidylcholine with shock lymph enters the bloodstream and from there, mainly associated with high density lipoproteins to the liver form.
Pharmacokinetics studies in humans were conducted using dilinoleil-phosphatidylcholine radiolabeled (3 H and 14 C).
Choline part was labeled with 3 H and the residue was linoleic acid as a tag 14C.
The maximum concentration is achieved after 3 H 6-24 hours after administration and is 19.9% of the prescribed dose. The half-life choline component is 66 hours.
14C maximum concentration achieved after 4-12 hours after administration and up to 27.9% of the prescribed dose. The half-life of this component is 32 hours.
Both isotopes of more than 90% absorbed in the intestine.
Conditions of supply of pharmacies
Without a prescription.
side effects
Esslial forte drug is usually well tolerated by patients. In order to assess the incidence of side effects following definitions are used: very often (> 1/10), often (> 1/100 – 1/1000 – 1/10000 –
On the part of the gastrointestinal tract: rarely – discomfort in the epigastric region, loose stools, nausea, gastralgia.
Allergic reactions: seldom – rash, rash, urticaria; unknown frequency – itching.
special instructions
Effects on ability to drive and use machines
Does not affect
Storage conditions
In the dark place at a temperature not higher than 25 ° C.
Keep out of the reach of children.
Dosing and Administration
Inside. The capsules should be taken as a whole, squeezed with sufficient water (about 1 cup).
For teenagers over 12 years weighing more than 43 kg, as well as for adult drug Esslial forte it is recommended to take 2 capsules – 3 times a day during meal time.
Typically, the duration of administration is not limited.
Information
Appearance may differ from that depicted in the picture. There are contraindications. You need to read the manual or consult with a specialist
There are no reviews yet.